These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 32173127)

  • 1. Re: Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance.
    Llorente C
    Eur Urol; 2020 Jun; 77(6):756-757. PubMed ID: 32173127
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol 2020;77:501-7.
    Simpson BS; Carmona Echeverria LM; Norris JM; Ahmed HU; Moore CM; Whitaker HC
    Eur Urol; 2020 Sep; 78(3):e106-e107. PubMed ID: 32527691
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.009.
    Du J; Liu Y; Yan W
    Eur Urol; 2020 Aug; 78(2):e64. PubMed ID: 32362499
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Jianhui Du, Yueguang Liu, and Weigang Yan's Letter to the Editor re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.009.
    Chesnut GT; Vertosick EA; Ehdaie B
    Eur Urol; 2020 Aug; 78(2):e65-e66. PubMed ID: 32386781
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
    Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
    Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression and treatment rates using an active surveillance protocol incorporating image-guided baseline biopsies and multiparametric magnetic resonance imaging monitoring for men with favourable-risk prostate cancer.
    Thurtle D; Barrett T; Thankappan-Nair V; Koo B; Warren A; Kastner C; Saeb-Parsy K; Kimberley-Duffell J; Gnanapragasam VJ
    BJU Int; 2018 Jul; 122(1):59-65. PubMed ID: 29438586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value.
    Felker ER; Wu J; Natarajan S; Margolis DJ; Raman SS; Huang J; Dorey F; Marks LS
    J Urol; 2016 May; 195(5):1421-1427. PubMed ID: 26674305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reply to Benjamin S. Simpson, Lina M. Carmona Echeverria, Joseph M. Norris, Hashim U. Ahmed, Caroline M. Moore, and Hayley C. Whitaker's Letter to the Editor re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol 2020;77:501-7.
    Chesnut GT; Vickers AJ; Ehdaie B
    Eur Urol; 2020 Sep; 78(3):e108-e109. PubMed ID: 32522388
    [No Abstract]   [Full Text] [Related]  

  • 9. Confirmatory Magnetic Resonance Imaging with or without Biopsy Impacts Decision Making in Newly Diagnosed Favorable Risk Prostate Cancer.
    Ginsburg KB; Arcot R; Qi J; Linsell SM; Kaye DR; George AK; Cher ML;
    J Urol; 2019 May; 201(5):923-928. PubMed ID: 30694939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Super active surveillance for low-risk prostate cancer | Opinion: No.
    Ghodoussipour S; Lebastchi AH; Bloom JB; Pinto PA; Berger A
    Int Braz J Urol; 2019; 45(2):215-219. PubMed ID: 31021585
    [No Abstract]   [Full Text] [Related]  

  • 11. Latest Evidence on the Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Insignificant Prostate Cancer: A Systematic Review.
    Cantiello F; Manno S; Russo GI; Cimino S; Privitera S; Morgia G; Cicione A; Damiano R
    Anticancer Agents Med Chem; 2018; 18(7):925-930. PubMed ID: 29303080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging Characteristics of Prostate Cancer Patients Who Discontinued Active Surveillance on 3-T Multiparametric Prostate MRI.
    Habibian DJ; Liu CC; Dao A; Kosinski KE; Katz AE
    AJR Am J Roentgenol; 2017 Mar; 208(3):564-569. PubMed ID: 28075651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
    Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
    J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
    Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
    Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.
    Recabal P; Assel M; Sjoberg DD; Lee D; Laudone VP; Touijer K; Eastham JA; Vargas HA; Coleman J; Ehdaie B
    J Urol; 2016 Aug; 196(2):374-81. PubMed ID: 26920465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer: rationale and design.
    Ahlberg MS; Adami HO; Beckmann K; Bertilsson H; Bratt O; Cahill D; Egevad L; Garmo H; Holmberg L; Johansson E; Rannikko A; Van Hemelrijck M; Jäderling F; Wassberg C; Åberg UWN; Bill-Axelson A
    BMJ Open; 2019 Aug; 9(8):e027860. PubMed ID: 31444180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443-51.
    Chu CE; Lonergan PE; Carroll PR
    Eur Urol; 2020 Sep; 78(3):e110-e111. PubMed ID: 32622551
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443-51.
    Montorsi F; Gandaglia G; Fossati N; Salonia A; Briganti A
    Eur Urol; 2020 Oct; 78(4):e165. PubMed ID: 32798145
    [No Abstract]   [Full Text] [Related]  

  • 19. The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer.
    Schulman AA; Sze C; Tsivian E; Gupta RT; Moul JW; Polascik TJ
    Curr Urol Rep; 2017 Jul; 18(7):52. PubMed ID: 28589398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic Resonance Imaging for Tailoring the Need to Biopsy During Follow-up for Men on Active Surveillance for Prostate Cancer.
    Padhani AR; Rouvière O; Schoots IG
    Eur Urol; 2021 Nov; 80(5):564-566. PubMed ID: 34053779
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.